340B Drug Pricing Program Policy Papers

BACK TO 340B MAIN POLICY PAGE

• REBATE VS. REVENUE: The Accountability Crisis Threatening the 340B Program (March 2026)

• The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities – Supplemental Report 2 (December 2025)

• Patient Medical Debt: Findings from Quantitative Surveying of Patients in the United States (April 2025)

  • En español

• Is the 340B Drug Pricing Program the Next 'Too Big to Fail'? (March 2025)

  • En español

• The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities – Supplemental Report (February 2025)

  • En español

• The 340B Drug Pricing Program and its Potential Impacts on Annual Revenues, Executive Compensation, and Charity Care Provision in Eligible Covered Entities (July 2024)

  • En español

BACK TO 340B MAIN POLICY PAGE